OrbiMed Advisors LLC is a healthcare-focused investment firm founded in 1989, managing approximately $5 billion in assets. The firm specializes in a range of investment strategies, including private equity, venture capital, and public equity, targeting companies across the healthcare spectrum—from startups to large multinational corporations. OrbiMed invests in various sectors within the healthcare industry, including pharmaceuticals, biotechnology, life sciences, medical devices, and health IT. The firm typically invests between $3 million and $150 million, often seeking majority stakes in its portfolio companies. With a global investment approach, OrbiMed operates from offices in New York, San Francisco, Mumbai, Herzliya, Shanghai, West Kowloon, and Luxembourg, focusing on opportunities in North America, Europe, Asia, and Israel. Its investment strategies are underpinned by fundamental analysis, encompassing investments in public equity, fixed income, and alternative markets.
ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.
TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution.
Terns Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing molecularly targeted, oral small-molecule drugs aimed at treating cancer and liver diseases. Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, China, Terns leverages its expertise in disease biology and medicinal chemistry to advance its drug pipeline. Notable products include TERN-101, a potent farnesoid X receptor agonist, and TERN-201, a semicarbazide-sensitive amine oxidase inhibitor. The company emphasizes a capital-efficient drug discovery model and has extensive clinical development capabilities in China, striving to bring innovative therapeutic candidates to address significant unmet medical needs both locally and globally.
I-Mab HK develops drugs to treat diabetes, cancer, and autoimmune diseases. The company develops preclinical compounds, including GX-P2; a long-acting PD-L1 drug for the treatment of inflammatory bowel diseases and GX-G8; a long-acting GLP-2 drug for the treatment of chemotherapy-induced diarrhea and short bowel syndrome. The company was formerly known as Tianzhenshi Biotechnology Company and changed its name to I-Mab HK in March 2017. The company is headquartered in Tianjin, China.
ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.
PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.
PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.
Foamix Pharmaceuticals Inc. a pharmaceutical company, engages in development and commercialization of proprietary, innovative, and differentiated topical drugs for dermatological conditions. It offers Molecule Stabilizing Technology (MST) platform. The company was incorporated in 2014 and is based in Bridgewater, New Jersey. Foamix Pharmaceuticals Inc. operates as a subsidiary of Menlo Therapeutics Inc.
Terns Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing molecularly targeted, oral small-molecule drugs aimed at treating cancer and liver diseases. Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, China, Terns leverages its expertise in disease biology and medicinal chemistry to advance its drug pipeline. Notable products include TERN-101, a potent farnesoid X receptor agonist, and TERN-201, a semicarbazide-sensitive amine oxidase inhibitor. The company emphasizes a capital-efficient drug discovery model and has extensive clinical development capabilities in China, striving to bring innovative therapeutic candidates to address significant unmet medical needs both locally and globally.
Modis Therapeutics, Inc. is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases with significant unmet medical needs. The company, based in Oakland, California, was incorporated in 2016 and is a subsidiary of Zogenix, Inc. Modis Therapeutics is advancing its lead therapy, MT1621, which aims to restore mitochondrial DNA replication fidelity. This therapeutic candidate is specifically designed to address thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disorder. By improving nucleotide balance, increasing mitochondrial DNA copy number, and enhancing cell function, Modis Therapeutics aims to provide meaningful treatment options that can prolong the lives of affected patients.
Foamix Pharmaceuticals Inc. a pharmaceutical company, engages in development and commercialization of proprietary, innovative, and differentiated topical drugs for dermatological conditions. It offers Molecule Stabilizing Technology (MST) platform. The company was incorporated in 2014 and is based in Bridgewater, New Jersey. Foamix Pharmaceuticals Inc. operates as a subsidiary of Menlo Therapeutics Inc.
PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, kidney transplant, dermatology, and neurological space. True North was formed in 2013 as a spin-out of iPierian.
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, kidney transplant, dermatology, and neurological space. True North was formed in 2013 as a spin-out of iPierian.
PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.
MethylGene Inc. (TSX:MYG) is a publicly-traded, clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics with a focus on cancer. The Company's product candidates include: MGCD265, an oral, multi-targeted kinase inhibitor targeting the Met, VEGF, Ron and Tie-2 receptor tyrosine kinases that is in multiple clinical trials for cancer; MGCD290, a fungal Hos2 inhibitor for use in combination with fluconazole for serious fungal infections which has completed Phase I clinical studies; and mocetinostat (MGCD0103), an oral, isoform-selective HDAC inhibitor for cancer which has been in multiple Phase II clinical trials and is currently in a Phase II trial in refractory or relapsed follicular lymphoma. Mocetinostat is licensed to Taiho Pharmaceutical Co. Ltd in certain Asian countries. A fourth compound discovered using MethylGene's HDAC platform, EVP-0334 - a potential cognition enhancing agent for neurodegenerative diseases has successfully completed Phase I trials sponsored by EnVivo Pharmaceuticals Inc. MethylGene also has a funded collaboration with Otsuka Pharmaceutical Co. Ltd. for applications in ocular diseases using the Company's proprietary kinase inhibitor chemistry.
Arteaus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for the prevention of migraines. The company focuses on creating drugs that target calcitonin gene-related peptide (CGRP), a key molecule involved in the migraine pathway. By developing antibodies that inhibit CGRP, Arteaus aims to provide effective treatment options for individuals suffering from migraine headaches.
Arteaus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for the prevention of migraines. The company focuses on creating drugs that target calcitonin gene-related peptide (CGRP), a key molecule involved in the migraine pathway. By developing antibodies that inhibit CGRP, Arteaus aims to provide effective treatment options for individuals suffering from migraine headaches.
SMT is a Herzliya Pituach, Israel-based medical device company founded in 2004. SMT is focused on the development and commercialization of procedural tools and accessories for use during TAVI and other complex percutaneous structural heart procedures.
Targanta Therapeutics a biopharmaceutical company focused on the development and commercialization of innovative antibiotics for serious infections treated or acquired in hospitals and other institutional settings.